Veterinary Dermatology Drugs Market Report 2025

The veterinary dermatology drugs market size has grown rapidly in recent years. It will grow from $8.6 billion in 2024 to $9.57 billion in 2025 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to prevalence of dermatological conditions, increased veterinary spending, changing environmental factors, companion animal healthcare awareness, regulatory approvals, zoonotic disease awareness.

The veterinary dermatology drugs market size is expected to see rapid growth in the next few years. It will grow to $14.81 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to growing pet insurance adoption, rising incidence of allergies, globalization of pet products, holistic pet care approach, companion animal population growth, consumer education. Major trends in the forecast period include advancements in veterinary dermatology research, focus on allergy management, demand for topical treatments, nutraceuticals and dermatological health, telemedicine in veterinary dermatology, customized and personalized therapies, pet insurance and healthcare spending.

The growing number of pet owners is anticipated to boost the veterinary dermatology drugs market in the future. Pet owners are those who own or adopt animals and are responsible for their pets' health and well-being, providing necessary medical care, which in turn increases the demand for veterinary medications. For example, in 2022, Animal Medicines Australia, a non-governmental organization based in Australia, reported a significant rise in pet ownership, with the number of pet owners reaching 28,730.8, a 24% increase from 39% in 2021. This highlights a strong upward trend in pet adoption and investment in pet care, reflecting the growing popularity of pets in Australian homes. As a result, the increasing number of pet owners is driving the veterinary dermatology drugs market.

The rise in the burden of dermatological diseases is expected to contribute significantly to the growth of the veterinary dermatology drugs market. Dermatological diseases encompass a broad spectrum of medical conditions affecting the skin, influenced by factors such as genetics, environmental elements, allergies, infections, and lifestyle changes in animals. Owners, recognizing the importance of their animals' well-being, are increasingly seeking veterinary care for dermatological issues. Additionally, the awareness of zoonotic diseases, which can be transmitted between animals and humans, emphasizes the importance of managing and treating skin conditions in animals. As an example, in October 2022, a report from the British Broadcasting Corporation highlighted the impact of lumpy skin disease on over 2.4 million animals in India, leading to the death of more than 110,000 cattle. The rising burden of dermatological diseases is a significant factor driving the growth of the veterinary dermatology drugs market.

In the pursuit of sustaining their market position, major companies in the veterinary dermatology drugs market are innovating by introducing new enzyme-based healthcare solutions. For instance, in October 2022, Pet King Brands Inc., a US-based pet care company, expanded its ZYMOX Enzymatic Dermatology product line with three new offerings specifically designed for cats and kittens. These products, featuring feline-centric packaging and the Seal of Endorsement from The International Cat Association (TICA), aim to address ear and skin conditions in felines without the use of antibiotics or harsh ingredients. The ZYMOX for Cats and Kittens range includes Enzymatic Ear Solution with 0.5% Hydrocortisone, Enzymatic Ear Cleanser, and Enzymatic Topical Cream with 0.5% Hydrocortisone. Leveraging the patented LP3 Enzyme System, these products offer effective solutions for common feline conditions such as ear infections, irritated skin, hot spots, ringworm, and acne.

Major players in the veterinary dermatology drugs market are strategically forming partnerships to broaden their offerings. Strategic partnerships involve companies combining their strengths and resources to achieve mutual benefits and success. For example, in January 2022, Dechra, a UK-based specialist in veterinary pharmaceuticals and related products, entered into a partnership with Bioiberica, a life science company specializing in veterinary pharmaceuticals. The collaboration involves the licensing and distribution of the Atopivet line of dermatological products for cats and dogs in the US, aiming to enhance the health and wellbeing of humans, animals, and plants.

In January 2023, Animal Dermatology Group, Inc., a US-based veterinary dermatology firm, acquired Golden Gate Veterinary Specialists for an undisclosed sum. This acquisition is intended to enhance Animal Dermatology Group's ability to offer specialized veterinary services by integrating Golden Gate Veterinary Specialists. This move will expand their team of over 80 veterinary specialists and reinforce their commitment to providing high-quality, individualized care in dermatology, oncology, and internal medicine to meet the increasing demand for outpatient veterinary specialty services. Golden Gate Veterinary Specialists is a US-based practice specializing in dermatological and surgical care.

Major companies operating in the veterinary dermatology drugs market are Elanco Animal Health Inc., Merk & Co. Inc., Zoetis Inc., Vetoquinol SA, Ceva Santé Animale, Virbac S.A., Bimeda Inc., IDEXX Laboratories Inc. SavaVet, Vetmedica, Mars Incorporated, Kindred Biosciences, Bayer Animal Health, Boehringer Ingelheim Vetmedica, Dechra Pharmaceuticals PLC, Norbrook Laboratories Limited, Veterinary Centers of America Inc., Heska Corporation, Biogénesis Bagó, Nexvet, Aratana Therapeutics.

North America was the largest region in the veterinary dermatology drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the veterinary dermatology drugs market report forecast period. The regions covered in the veterinary dermatology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary dermatology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Veterinary dermatology drugs are medications specifically formulated to address skin conditions in animals, such as infections, allergies, and parasites. These treatments are utilized to relieve itching, reduce inflammation, and facilitate skin healing. By addressing dermatological issues, these drugs contribute to enhancing the overall health and comfort of affected animals.

The primary categories of veterinary dermatology drugs include antifungal drugs, antibacterial drugs, and antiparasitic drugs. Antifungals are pharmaceuticals that inhibit the growth of fungi responsible for infections commonly affecting the skin, hair, and nails of animals. These drugs are administered through various routes, including topical, injectable, and oral methods. The target recipients of these medications are diverse, ranging from companion animals to livestock. The drugs are utilized for indications such as parasitic infections and allergic reactions. Distribution channels for veterinary dermatology drugs encompass retail outlets, hospital pharmacies, and online platforms.

The veterinary dermatology drugs market research report is one of a series of new reports that provides veterinary dermatology drugs market statistics, including veterinary dermatology drugs industry global market size, regional shares, competitors with a veterinary dermatology drugs market share, detailed veterinary dermatology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary dermatology drugs industry. This veterinary dermatology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The veterinary dermatology drugs market consists of sales of dicloxacillin, erythromycin, tetracycline, and retinoids, which are naturally occurring and synthetic compounds with vitamin A activity. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.